Engitix, a London-based BioTech focused on the extracellular matrix, closed a €21 mn Series A extension, about $25 mn, to move its cancer and fibrosis programs deeper into development.
Startup targets the ECM, a layer of biology many drug platforms still struggle to read, let alone treat.
The capital came from Netherton Investments, which invests on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management. One investor. Full extension. No syndicate reshuffle.
Giuseppe Mazza, CEO and co-founder of Engitix, said the financing strengthens the company’s ability to turn its ECM datasets into a broader pipeline of targeted therapeutics.
He pointed to faster preclinical progress across oncology and fibrosis, and to drug candidates designed to act inside diseased tissue rather than around it.
Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics
Giuseppe Mazza, CEO and co-founder of Engitix
“Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes,” said Giuseppe Mazza.
The raise lands inside a steady run of European BioTech funding seen through 2025, especially across oncology and fibrosis. Mid-stage rounds didn’t slow much, even as later-stage capital became more selective.
- Comparable deals include TargED Biopharmaceuticals in the Netherlands, which raised €21.5 mn to advance thrombotic disease therapies. Larger cheques followed elsewhere.
- Switzerland-based FoRx Therapeutics secured €42 mn for DNA-repair cancer drugs. France’s Adcytherix pulled in €105 mn for antibody-drug conjugates. Germany’s Tubulis raised €308 mn to expand its ADC pipeline.
- The UK stayed busy too. Trogenix closed an €80 mn round to accelerate cancer programs. Scripta Therapeutics raised more than €10 mn for its platform work. Engitix fits neatly into that domestic cluster.
- Elsewhere in Europe, Italy-based NanoPhoria raised €83.5 mn for a heart failure therapy, while Ireland’s Aerska secured €17 mn for RNAi drugs targeting brain diseases. Add it all up and disclosed BioTech funding cleared €600 mn last year.
According to Beinsure analysts, that level suggests investors still back platforms that promise biological differentiation, not just speed.
Engitix was founded in 2016 to build therapies that target the ECM in cancer and fibrosis.
The company combines large-scale ECM datasets with translational biology and drug development, aiming to generate drugs that operate directly inside disease microenvironments. It’s a narrow bet, by design.
The company also runs a strategic drug discovery partnership with Dompé farmaceutici and maintains development collaborations with Takeda in advanced fibrotic liver disease. Those links add industrial weight, though they don’t remove development risk.
Mike Platt said Engitix sits at the intersection of data, biology, and drug development, and confirmed continued backing as the company advances its fibrosis and solid tumour programs.
The new funds will support preclinical work across Engitix’s ECM-targeted pipeline in solid tumours and fibrosis, and further expand its proprietary ECM platform, already described as one of the largest of its kind in these diseases. Whether that translates into clinical proof is the next, unfinished sentence.
